Bifunctional Compounds for Targeted BCL6 Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with overexpression or aggregation of B-cell lymphoma 6 protein (BCL6) are limited by non-specific effects and the inability to effectively target and modulate BCL6.
Innovation Solution
Development of bifunctional compounds that comprise an E3 ubiquitin ligase binding moiety and a target protein binding moiety, allowing for the recruitment of endogenous proteins to an E3 ubiquitin ligase for degradation, thereby modulating targeted ubiquitination and inhibiting BCL6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bifunctional compounds are developed to target BCL6 specifically, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The bifunctional compound is divided into two distinct functional moieties: a BCL6 binding moiety that specifically recognizes and binds to BCL6 protein, and an E3 ubiquitin ligase binding moiety that recruits the ubiquitination machinery. This segmentation allows each moiety to perform its specific function independently while working together to achieve targeted BCL6 degradation, resolving the contradiction between therapeutic efficacy and structural complexity.
Solution Approach 2:
The bifunctional compound acts as an intermediary molecule that bridges BCL6 and the E3 ubiquitin ligase system. By incorporating both binding sites into a single molecular structure, it mediates the interaction between the target protein (BCL6) and the degradation machinery (E3 ligase), enabling specific therapeutic action while maintaining a manageable molecular architecture.
2Reliability
If bifunctional compounds are used to degrade BCL6, then protein degradation is achieved, but manufacturing complexity increases
Solution Approach 1:
The compound structure is segmented into modular functional units (BCL6 binding moiety and E3 ligase binding moiety) that can be independently optimized and synthesized. This modularity facilitates standardized synthesis protocols and simplifies manufacturing processes by allowing each functional segment to be produced separately and then assembled into the complete bifunctional molecule.
Solution Approach 2:
The bifunctional compound design incorporates universal binding principles that can be applied across different target proteins. The E3 ligase binding moiety uses a conserved interaction mechanism that works with various E3 ligases, while the BCL6 binding moiety follows established small molecule recognition patterns, making the overall synthesis approach transferable and manufacturable.
Data Source
AI summary
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.